Developing an HPV vaccine to prevent cervical cancer and genital warts

Vaccine

Volumn 25, Issue 16 SPEC. ISS., 2007, Pages 3001-3006

  Bryan, Janine T ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Gardasil ; HPV vaccine; HPV virus like particles

Indexed keywords

ALUMINUM; CAPSID PROTEIN; PHOSPHATE; SULFATE; WART VIRUS VACCINE;

ARTICLE; CLINICAL PROTOCOL; CONDYLOMA; DYSPLASIA; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOGENICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; SAFETY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRION; VIRUS IDENTIFICATION; VIRUS LIKE AGENT; WART VIRUS; YEAST;

EID: 33947586116     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.01.013     Document Type: Article

References (50)

1. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 1 (1999) 12-19
2. Ferlay J, Bray F, Pisani P. GLOBOCAN 2002 cancer incidence. Mortality and prevalence worldwide. IARC CanerBase No. 5 version2.0 Lyon: IARC Press, 2004.
3. World Health Organization (WHO). Vaccines against human papillomavirus Available at: http://www.who.int/vaccines/en/hpvrd.shtml/shtml Access 2004.
4. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. for the International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-27.
5. Daling J.R., Madeleine M.M., Schwartz S.M., Shera K.A., Carter J.J., McKnight B., et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol 84 (2002) 263-270
6. Madeleine M.M., Daling J.R., Carter J.J., Wipf G.C., Schwartz S.M., McKnight B., et al. Cofactors with human papillomavirus in a population-based study of vulvar cancer. J Natl Cancer Inst 89 (1997) 1516-1523
7. Frisch M. On the etiology of anal squamous carcinoma. Dan Med Bull 49 (2002) 194-209
8. Partridge J.M., and Koutsky L.A. Genital human papillomavirus infection in men. Lancet Infect Dis 6 (2006) 21-31
9. Wiley D.J., Douglas J., Beutner K., Cox T., Fife K., Moscicki A.B., et al. External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis 35 (2002) S210-S224
10. Somers G.R., Tabrizi S.N., Borg A.J., Garland S.M., and Chow C.W. Juvenile laryngeal papillomatosis in a pediatric population: a clinicopathologic study. Pediatr Path Lab Med 17 (1997) 53-64
11. Derkay C.S., and Darrow D.H. Recurrent respiratory papillomatosis of the larynx: current diagnosis and treatment. Otolaryngol Clin North Am 33 (2000) 1127-1141
12. Green G.E., Bauman N.M., and Smith R.J.H. Pathogenesis and treatment of juvenile onset recurrent respiratory papillomatosis. Otolaryngol Clin North Am 33 (2000) 187-207
13. Zhou J., Sun X.Y., Stenzel D.J., and Frazer I.H. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 185 (1991) 251-257
14. Kirbauer R., Booy F., Chang N., Lowy D.R., and Schiller J.T. Papillomavirus L1 major immunogenic. Proc Natl Acad Sci USA 89 (1992) 12180-12184
15. Rose R.C., Bonnez W., Reichman R.C., and Garcea R.L. Expression of HPV type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol 67 4 (1993) 1936-1944
16. Hagensee M.E., Yaegashi N., and Galloway D. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol 67 (1993) 315-322
17. West D.J. Scope and design of hepatitis B vaccine clinical trials. In: Ellis R.W. (Ed). Hepatitis B vaccines in clinical practice (1993), Marcel Dekker, New York 159-177
18. Hofmann K.J., Cook J.C., Joyce J.G., Brown D.R., Schultz L.D., George H.A., et al. Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiae. Virology 209 (1995) 506-518
19. Hofmann K.J., Neeper M.P., Markus H.Z., Brown D.R., Muller M., and Jansen K.U. Sequence conservation within the major capsid protein of human papillomavirus (HPV) type 18 and formation of HPV-18 virus-like particles in Saccharomyces cerevisiae. J Gen Virol 77 (1996) 465-468
20. Brown D.R., Bryan J.T., Cramer H., and Fife K.H. Analysis of human papillomavirus types in condylomata acuminate by hybrid capture and Southern blot techniques. J Clin Microbiol 31 (1993) 2667-2673
21. Neeper M.P., Hofmann K.J., and Jansen J.U. Expression of the major capsid protein of human papillomavirus type 11 in Saccharomyces cerevisiae. Gene 180 (1996) 1-6
22. Cook J.C., Joyce J.G., George H.A., Schutlz L.D., Hurni W.M., Jansen K.U., et al. Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiae. Protein Expr Purif 17 (1999) 477-484
23. ®, a recombinant HPV vaccine. Presented at the 23rd International Papillomavirus Conference, Prague, Czech Republic; 2006.
24. Dillner J., and Brown D.R. Can genital-tract human papillomavirus infection and cervical cancer be prevented with a vaccine?. Expert Rev Mol Med 6 (2004) 1-21
25. Brown D.R., Bryan J.T., Schroeder J.M., Robinson T.S., Fife K.H., Wheeler C.M., et al. Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titers. J Infect Dis 284 (2001) 1186-2283
26. Brown D.R., Fife K.H., Wheeler C.W., Koutsky L.A., Lupinacci L.M., Railkar R., et al. Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. Vaccine 22 (2004) 2936-2942
27. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347 21 (2002) 1645-1651
28. Ault K., Guilliano A.R., Edwards R., Tamms G., Kim L.L., Smith J.F., et al. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP Vaccine. Vaccine 22 (2004) 3004-3007
29. Fife K.H., Wheeler C.W., Koutsky L.A., Barr E., Brown D.R., Schiff M.A., et al. Dose-ranging studies of the safety and immunogenicity of human papillomavirus type 11 and type 16 virus-like particles candidate vaccines in young healthy women. Vaccine 22 (2004) 2943-2952
30. Shi L., Sanyal G., Ni A., Luo Z., Doshna S., Wang B., et al. Stabilization of human papillomavirus virus-like particles by non-ionic surfactants. J Pharm Sci 94 (2005) 1538-1551
31. Vogel F.R., and Powell M.F. A compendium of vaccine adjuvants and excipients. Pharm Biotechnol 6 (1995) 141-228
32. HogenEsch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 20 Suppl. 3 (2002) S34-S39
33. Wang S., Liu X., and Caulfield M.J. Adjuvant synergy in the response to hepatitis B vaccines. Vaccine 21 27-28 (2003) 4297-4306
34. Ruiz W., McClements W.L., Jansen K.U., and Esser M.T. Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant. J Immune Based Therapies Vaccines 3 2 (2005) 1-11
35. Hem S.L., and White J.L. Structure and properties of aluminum-containing adjuvants. In: Powell M., and Newman M. (Eds). Vaccine design: the subunit and adjuvant approach (1995), Plenum Press, New York 249-276
36. Shirodkar S., Hutchinson R.L., Perry D.L., White J.L., and Hem S.L. Aluminum compounds used as adjuvants in vaccines. Pharm Res 7 12 (1990) 1282-1288
37. al-Shakhshir R., Regnier F., White J.L., and Hem S.L. Effect of protein adsorption on the surface charge characteristics of aluminium-containing adjuvants. Vaccine 12 5 (1994) 472-474
38. Caulfield MJ, Shi L, Wang S, Wang B, Tobery TW, Mach H, et al. Effects of alternative aluminum adjuvants on the absorption and immunogenicity of HPV 16 L1 VLPs in mice. Submitted for publication.
39. Ruiz W, Barr E, Bryan J, Sings H, Sikkema D, Esser MT. Long-term antibody responses following immunization with a quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1-virus-like particle vaccine in comparison to natural infection with human papillomavirus. Submitted for publication.
40. Opalka D., Lachman C.E., MacMullen S.A., Jansen K.U., Smith J.F., Chirmule N., et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16 and 18 by multiplexed Luminex assay. Clin Diag Lab Imm 10 (2003) 108-115
41. Dias D., VanDoren J., Schlottmanns, Kelly S., Puchalski D., Ruiz W., et al. Optimization and validation of a multiplex Luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16 and 18. Clin Diag Lab Imm 12 (2005) 959-969
42. Christensen N.D., Krieder J.W., Cladel N.M., Patrick S.D., and Welsh P.A. Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11. J Virol 64 (1990) 5678-5681
43. Christensen N.D., Dillner J., Eklund C., Carter J.J., Wipf G.C., Reed C.A., et al. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 223 (1996) 174-184
44. Christensen N.D., Kirnbauer R., Schiller J.T., Ghim S.J., Schlegel R., Jenson A.B., et al. Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. Virology 205 (1994) 329-335
45. Villa L.L., Costa R.L.R., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylatic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase 11 efficacy trial. Lancet Oncol 6 (2005) 271-278
46. Villa L.L., Ault K.A., Giuliano A.R., Costa R.L., Petta C.A., Andrade R.P., et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16 and 18. Vaccine 7 (2006) 27-28
47. Block S.L., Nolan T., Sattler C., Barr E., Giacoletti K.E.D., Marchant C.D., et al. For the Protocol 016 Study Group. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (type 6, 11, 16 and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118 (2006) 2135-2145
48. Solomon D., Davey D., Kurman R., Moriarty A., O'Connor D., Prey M., et al. for the Forum Group Members and the Bethesda 2001 Workshop. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 287 (2002) 2114-2119
49. Taddeo FJ, Iftner T, Germ L, Swoyer R, Kruger Kjaer S, Breugelmans G, et al. The Genotyping Assay that Determined the Efficacy of GARDASIL™: A Comparison Study between the HPV Real Time Multiplex PCR Assay and Hybrid Capture II and INNO-LiPA HPV Genotyping PCR Assays. Presented at the 23rd International Papillomavirus Conference, Prague, Czech Republic. Sept 2006.
50. Villa LL, Costa RLR, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Induction of Immune Memory Following Administration of a Prophylactic Quadrivalent Human Papillomavirus (HPV) Types 6/11/16/18 L1 Virus-Like Particle (VLP) Vaccine. Presented at the International Conference on Infectious Disease, Lisbon, Portugal. June 2006.